EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma

Alexandru Corlateanu, Cristina Toma

Exploration of Asthma & Allergy · 2025

DOI: 10.37349/eaa.2025.1009104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Asthma & Allergy, 2025. Verfasst von Alexandru Corlateanu und 1 weiteren Autor:innen. Die Arbeit nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diversity of physiological actions and pharmacological effects of glucocorticoids (GCs) allows their use in a large group of diseases and pathological conditions. However, this treatment can be accompanied by a multitude of more or less severe side effects. As the mainstay of treatment for asthma and chronic obstructive pulmonary disease (COPD), inhaled corticosteroids (ICS) dramatically reduce morbidity and mortality. This research aims to examine the safety considerations associated with glucocorticoid therapy in patients with COPD and asthma.

Methods

The search was performed in PubMed, EBSCO, UpToDate, Medline, and Google Scholar for pertinent English-language articles published between 1990 and 2025, using the following keywords: glucocorticoids, asthma, COPD, management, and side effects.

Results

GCs stand out as one of the most widely prescribed classes of drugs globally, with well-established effectiveness in addressing acute or chronic inflammation, allergic conditions, and acute pathological situations. The undeniable efficacy of GCs, however, comes with a range of reported side effects. These include but are not limited to immunosuppression, cardiovascular issues, manifestation of Cushingoid features, development of diabetes, osteoporosis, suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and adverse effects on the gastrointestinal and dermatologic systems. However, the majority of these events are associated with systemic drug administration, which is less commonly indicated in the treatment of COPD and asthma. There are several factors and specific considerations when deciding on GC treatment in COPD. In the context of corticosteroid treatment for asthma, the overarching impact involves the suppression of inflammatory genes, leading to reduced transcription of genes responsible for cytokines, chemokines, adhesion molecules, inflammatory enzymes, and receptors.

Discussion

GCs are associated with fewer side effects in both COPD and asthma treatment. It’s crucial to take into account factors such as the patient’s overall health, the severity of symptoms, the presence of comorbidities, and the responsiveness of specific features to GCs therapy.

Zitieren

APA

Corlateanu, A., & Toma, C. (2025). Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma. Exploration of Asthma & Allergy. https://doi.org/10.37349/eaa.2025.1009104

Vancouver

Corlateanu A, Toma C. Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma. Exploration of Asthma & Allergy. 2025. doi:10.37349/eaa.2025.1009104

BibTeX
@article{Corlateanu2025,
  author = {Corlateanu, Alexandru and Toma, Cristina},
  title = {Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma},
  journal = {Exploration of Asthma & Allergy},
  year = {2025},
  doi = {10.37349/eaa.2025.1009104}
}
Kostenlos starten →